India, May 23 -- Gilead Sciences, Inc. (GILD) Friday announced positive topline results from the Phase 3 ASCENT-03 study of Trodelvy in patients with first-line metastatic triple-negative breast cancer (mTNBC).
The study met its primary goal showing statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy in patients with first-line mTNBC
The safety profile of Trodelvy in the ASCENT-03 study was consistent with prior studies, and no new safety signals were identified.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
Phase 3 studies of Trodelvy across HER2- breast cancer including the ASCENT-07 trial in patients with HR+/HER2- mBC who h...